Ann: Positive DARRT-1 Data in Late-Stage Prostate Cancer, page-28

Stayso- this isn’t about what an imaginary patient thinks It’s simply about getting important facts correct. This is an oncology company communicating trial results in a price sensitive document and it’s important to report info about key study endpoints accurately. In fact I’d argue this is particularly important in oncology trials given the expectations that can be set. It may just be an honest error but their tumour response rate according to accepted definitions is out by a factor of 10! Do you not think it needs to be right? I’m interested in the concept and thinking of investing as it happens.